ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1971

PLCG2 Variants Influence CVID Susceptibility: Expanding the Spectrum of PLCG2-Associated Immune Dysregulation

Ann Marie Szymanski1, Kathleen Baysac1, Hannah Marcy1, Elizabeth Baskin1, Joshua Milner2 and Michael Ombrello1, 1Translational Genetics and Genomics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 2Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoimmunity, CVID, genetics and phospholipase, Immune Dysregulation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune dysregulation refers to alterations in immune signaling leading to development of autoimmunity, infection and atopic disease. Common variable immunodeficiency (CVID), a prototypic disorder of immune dysregulation, is characterized by hypogammaglobulinemia, recurrent infections, poor vaccine responses and diverse complications, including autoimmunity. Although small subsets of CVID have been linked with various genes, the larger genetic landscape of CVID is unknown. Two closely-related familial disorders of immune dysregulation — phospholipase C gamma 2 (PLCγ2) associated antibody deficiency and immune dysregulation (PLAID) and autoinflammatory PLAID (APLAID) — are caused by dominant mutations in PLCG2. These disorders are marked by antibody deficiency and immune dysregulation and are strikingly similar to that observed in CVID. We therefore hypothesized that genetic variants of PLCG2 influence CVID susceptibility.

Methods: Using a combination of Sanger sequencing and targeted deep resequencing, we examined the coding region of PLCG2 in 185 CVID patients and 96 local controls. Variant positions were evaluated for evolutionary conservation (GERP++, SiPhy) and the functional effects of missense changes were predicted (PolyPhen2, SIFT, MutationTaster). Distributions of rare, evolutionarily conserved PLCG2 variants were compared between CVID cases and 37,370 non-Finnish European (NFE) subjects from the Exome Aggregation Consortium using the Sequence Kernel Association Test (SKAT). Effects of PLCG2 mutations on cell activation were examined by overexpressing mutant constructs in a PLCG2 deficient DT40 B cell line.

Results: Among 185 CVID cases, we found 12 missense variants of PLCG2, including 7 rare and 2 novel variants. All rare variants occurred at evolutionarily conserved sites and were predicted to detrimentally affect protein function. Rare variants were observed in 23 CVID patients (12.4%) and SKAT revealed significant enrichment of rare, evolutionarily conserved PLCG2 variants in CVID patients compared to the NFE population (p=5.3E-5). Overexpression studies revealed alterations in downstream signaling in 7 CVID variants: relative to wild type PLCG2, 6 variants lead to basal increases in ERK phosphorylation, while 2 produced enhanced activation following IgM stimulation.

Conclusion: Rare, evolutionarily conserved missense variants of PLCG2 are significantly associated with CVID. Furthermore, most of the rare PLCG2 variants found in CVID patients cause abnormal downstream signaling, in vitro. Based on these results, we conclude that PLCG2 influences susceptibility to CVID. Investigations are ongoing to determine whether PLCG2 mutations predict specific phenotypes or disease courses in CVID.


Disclosure: A. M. Szymanski, None; K. Baysac, None; H. Marcy, None; E. Baskin, None; J. Milner, None; M. Ombrello, None.

To cite this abstract in AMA style:

Szymanski AM, Baysac K, Marcy H, Baskin E, Milner J, Ombrello M. PLCG2 Variants Influence CVID Susceptibility: Expanding the Spectrum of PLCG2-Associated Immune Dysregulation [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/plcg2-variants-influence-cvid-susceptibility-expanding-the-spectrum-of-plcg2-associated-immune-dysregulation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plcg2-variants-influence-cvid-susceptibility-expanding-the-spectrum-of-plcg2-associated-immune-dysregulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology